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Angiotensin II stimulates human fetal mesangial cell proliferation and
fibronectm biosynthesis by binding to AT1 receptors. The renin-angio-
tensin system is activated during vascular development and injury.
Furthermore, angiotensin II (Ang II) is a comitogen for fetal mesangial
cells in vitro and it may be important in vascular smooth cell growth in
disease states. Since fibronectin is an important extracellular matrix
protein for vascular development and it too is overexpressed in the
mesangium of diseased glomeruli, we explored the interrelationship of
fibronectin and Ang II in fetal mesangial cell growth. In human fetal
kidney, Ang II type 2 receptors (AT2) were detected in abundance by ex
vivo autoradiography. When mesangial cells were isolated from fetal
kidney and grown in culture, Mg II type 1 receptors (AT1) were also
detected. To explore the mitogenic properties Ang II and fibronectin as
well as the effects of Ang II on fibronectin metabolism, studies were
performed in vitro, isolated from the potentially confounding variables
of hemodynamic influence and circulating growth factors and cyto-
kines. In vitro, mesangial cells expressed a single class of AT1 receptors
that were not altered by growth on various substrates. Ang II (1O- M)
significantly increased thymidine incorporation by confluent human
fetal mesangial cells (twofold). When subconfluent, Ang Il-stimulated
proliferation was greater (fourfold). Ang II significantly increased
cell-associated and secreted fibronectin as determined by immunopre-
cipitation at concentrations that also stimulate mitogenesis. Both of
these Ang Il-mediated responses were inhibited by the AT1 receptor
antagonist DuP-753 (lO- M) but not by AT2 receptor antagonist. These
data suggest that when bound to AT1 receptors expressed on human
fetal mesangial cells, Ang II directly stimulates fibronectin production
and cellular proliferation independently of its effects on renal and
systemic hemodynamics. Furthermore, the AT1 receptor subtype may
well participate in the regulation of fibronectin synthesis during devel-
opment and in disease.
The vasoactive octapeptide angiotensin II (Ang II) has a
well-established role in cardiovascular hemodynamic regulation
but, increasingly, Ang II is recognized as a multifunctional
peptide that modulates cardiovascular development, cellular
proliferation, and the expression of growth-related genes. Re-
cently, Ang II has been found to promote growth in cardiovas-
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cular and renal tissues not only during development but in
disease states as well [1—6]. Furthermore, Ang II stimulates
synthesis of components of the extracellular matrix in mesan-
gial and smooth muscle cells in vitro [4, 7, 8]. These findings
may apply to renal disease; angiotensin converting enzyme
inhibitors, when administered to animals, can attenuate the
development of glomerular sclerosis in several models of renal
disease [5, 9] including the remnant kidney [10, 11], streptozo-
tocin-induced diabetes [12, 13], and high protein feeding of
aging rats [14].
Changes in the composition of the mesangial matrix may
impair glomerular function by altering mesangial contraction or
glomerular capillary surface area. The metabolism of extracel-
lular matrix proteins is altered during the process of glomerular
sclerosis but recent studies suggest that changes in fibronectin
synthesis in vascular smooth muscle cells, in particular, may
influence the conversion of these contractile cells to a protein
synthetic phenotype [15-.17]. Therefore, it is possible that
during kidney development as well as in disease states [18—20]
mesangial fibronectin synthesis affects the contractile response
of human mesangial cells and consequently glomerular hemo-
dynamic function.
Fibronectin is a widely distributed glycoprotein that is found
in a variety of extracellular matrices. Fibronectin can interact
with other matrix and cell-associated proteins to induce
changes in cell adhesion and migration [21, 22]. Through its
effects on cellular behavior, fibronectin plays a critical role in
embryonic development, tumor metastasis, and wound healing.
In the kidney, fibronectin is abundant in all interstitial areas of
the mature nephron as well as the glomerular mesangium [23].
In the embryonic kidney, changes in the location and distribu-
tion of fibronectin occur during mesenchymal differentiation
and epithelial development of the mature nephron [23, 24]. In
addition, the abundance of fibronectin in the glomerular me-
sangium increases in several primary glomerular diseases [25].
Thus, Ang II and fibronectin appear to play important roles in
renal development and disease and are often found to influence
similar target cells.
In the present study, we explored the interrelationship of
fibronectin and Ang II in fetal mesangial cells. Specifically, we
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examined the ability of Ang II, interracting with its receptors, to
induce human fetal mesangial cells to proliferate and to synthe-
size fibronectin. These studies were performed in vitro, to
isolate the direct cellular effects of Ang H from hemodynamic
influence.
Methods
Isolation and characterization of human fetal mesangial cells
Human fetal kidney was obtained in accordance with Na-
tional Institutes of Health guidelines from therapeutic abortions
performed at 15 weeks gestational age. Kidney glomeruli were
isolated according to standard techniques [3, 26]. Human fetal
mesangial cells were characterized as previously described [3,
26] by immunostaining using antibodies to Von Willebrand's
factor (Dakopatts, Denmark), human vimentin, smooth muscle
myosin, cytokeratin (Zymed, San Francisco, California, USA),
and mouse collagen type IV (Dr. Hynda Kleinman, National
Institutes of Health). Human fetal cells were used for these
studies since they are more responsive to the comitogenic
effects of Ang II in vitro [3].
Cells were grown in 50% Dulbecco's modified Eagles me-
dium, 50% Ham's F12 (Biofluids, Rockville, Maryland, USA)
containing 4.5 g/liter glucose, 20% heat-inactivated fetal calf
serum (Gibco, Grand Island, New York, USA), 2 msi glu-
tamine, 100 U/mI penicillin, 10 pg/ml streptomycin and 8 /hM
insulin. Human fetal mesangial cells were grown in 100 cm2
tissue culture plates (Falcon, Lincoln Park, New York, USA)
and studied between passages 4 and 11.
Measurements of Ang II receptors
[125I-Sar1,Ile]Ang II was prepared by modified chloramine-T
radioiodination and purified by HPLC using a C-18 column with
a (15:85) acetonitrile: 0.1 M ammonium bicarbonate buffer (pH
8.0). The specific activity of the isotope ranged from 1500 to
1800 mCi/sg as determined by radioreceptor assay using rat
adrenal gland capsular membranes [27]. Wells (16mm diameter)
were coated by dissolving 20 j.g of fibronectin or 20 ig of
laminin in 200 d of phosphate buffered saline for four hours at
37°C. Wells were then aspirated and cells were incubated in a
solution of 3% bovine serum albumin (BSA) and phosphate-
buffered saline for one hour at 37°C. BSA was removed by
aspiration before cell plating. For Ang II binding analysis, cells
were plated at 1 x iO cells/well in 24-well tissue culture plates
(16 mm diameter, Gibco) either not coated (plastic) or coated
with 20 zg fibronectin or laminin in the absence or presence of
20% FCS. Eighteen hours later, culture medium was removed,
and cells were washed twice with 1 ml phosphate buffered
saline, pH 7.4. Cells were then incubated with 100,000 cpm of
[1251-Sar1 ,ile8]Ang 11(0.25 nM) either in the presence of increas-
ing concentrations of unlabeled Ang II (Sigma, St Louis,
Missouri, USA) diluted in phosphate buffered saline with 0.1%
BSA, losartan Du Pont 753 (10—s M), or PD 123177 (10—6 M).
Cells were incubated in 0.5 ml medium 199 (Gibco ), containing
0.1% BSA and 0.5 msi EGTA for one hour at 37°C in a
humidified incubator under 95% air and 5% CO2. Binding
experiments were performed as previously described [3]. Spe-
cific binding was calculated from triplicate samples obtained by
subtracting the bound, nonspecific radioactivity from the
bound, total radioactivity. Nonspecific binding measured in the
presence of excess unlabeled Ang II (1 LM) was less than 10%
of the total binding in all experiments. Ang II binding experi-
ments were repeated three times. Binding affinity and receptor
concentration were calculated by computerized analysis as
described by Munson and Rodbard [28]. Cell counts were
performed in six individual wells in each experiment using a cell
counter (Coulter Electronics, Lanham, Maryland, USA). A
modified protocol [5, 29] was used to measure Ang II receptors
by autoradiography in a human fetal kidney section.
Effect of Ang II on cell number and DNA synthesis
Human fetal mesangial cells were plated in 24 well tissue
culture plates at 4 x l0 cells/cm2. The cells were made
quiescent by incubation in serum-free medium (with 8 tLM
insulin) for 48 hours. Based on our previous studies that
demonstrated maximum mitogenic effect of Ang II between 100
n and 1 sM (3), cells were incubated with one or more of the
following for 18 hours: vehicle, Ang 11(100 nM), angiotensin
converting enzyme inhibitor (100 nM), DuP 753 (losartan, I
LM), or PD 123177 (100 nM). After the 18 hour incubation, 1
pCi/mi of [3H]-thymidine was added to each well for an additional
four to six hours at 37°C. Wells were washed twice with phosphate
buffered saline and twice with ice-cold 5% TCA. The precipitate
was solubilized by the addition of 1 ml 0.25 N NaOH and 0.1%
SDS and incubated at 37°C for 30 minutes. One ml aliquots were
neutralized and added to 10 ml scintillation fluid and counted in a
liquid scintillation counter. In parallel experiments, cells were
detached with trypsin-EDTA and counted after 48 hours using a
cell counter as previously described [3].
Immunoprecipitation assay
Human fetal mesangial cells were plated in six well plates
(Costar, Cambridge, Massachusetts, USA), grown to conflu-
ence, and washed twice with phosphate buffered saline. Me-
dium was replaced with serum-free DMEM/F12 supplemented
with Nutridoma (Boehringer Mannheim Corp., Indianapolis,
Indiana, USA). After a 16 hour incubation, medium was
changed to methionine-free DMEM (Gibco) containing vehicle
or Ang II (1 pM) and incubated for 30 minutes. Cells were
labeled with 100 pCi/mi of L-[35S]-methionine (1000 Ci/mM,
Amersham Corp., Arlington Heights, illinois, USA) in methi-
onine-free medium supplemented with Ang II or vehicle. After
incubation for two hours, medium was collected and monolay-
ers were washed twice with phosphate buffered saline, and
lysed with extraction buffer (10 mM NaPO4, 150 mM NaCl, 10
mM EDTA, 0.02% Naazide, 0.1% SDS, 1%Triton X-100, 1
pg/ml aprotinin, 1 mi PMSF). Conditioned media and cell
lysates were analyzed by immunoprecipitation with rabbit
anti-human fibronectin antiserum (Collaborative Research Inc.,
Bedford, Massachusetts, USA). Cellular proteins were precip-
itated with 10% TCA, filtered on glass microfiber circles (What-
man International Ltd., Maidstone England, UK), and incor-
porated radioactivity was measured by liquid scintillation
counting. Protein lysates containing equal numbers of counts
were precipitated with protein G (Genex Corp., Gaithersburg,
Maryland, USA) and anti-fibronectin antibody, resuspended in
1% SDS, 15 g/m1 DTT, 0.1% bromophenol blue and 5%
glycerol and resolved by SDS-PAGE gel analysis. As a control,
anti-fibronectin antiserum was replaced with an equivalent
volume of normal rabbit serum.
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Fig. 1. Ang II receptor binding in sections
from human fetal kidney measured by ex vivo
autoradiography. A section from a human
fetal kidney was frozen in isopentane on solid
CO2 (—30°C). Tissue sections were cut in a
cryostat at — 14°C and mounted onto cold
gelatin-coated glass microscope slides.
Sections were incubated in binding buffer in
the presence of ['251-Sar',11e8 lAng 11(0.25
nM) and one of the following: phosphate
buffered saline with 0.1% BSA, 1 M
unlabeled Ang II, losartan (DuP 753, i0' M)
or PD 123177 (10_6 M) as described in the
Methods, Optical densities of the
autoradiograms were determined in 0.22 mm2
areas from kidney cortex (C) and medulla (M)
by computerized microdensitometry. PD
123177 (10—6 M) competed 80% of Ang II
specific binding in renal cortex and medulla
(lower right). In contrast, DuP 753 (10 M)
did not compete for Ang II binding (lower
left). These findings suggest that the majority
of Ang II receptors in fetal kidney detected by
in vitro autoradiography are AT2 receptors.
Northern analysis
Human fetal mesangial cells were plated in 150 x 25 mm
dishes at low density and treated with Ang II when subconfluent
and also when confluent. Cells were then washed twice with
phosphate buffered saline and incubated in serum-free DMEM/
F12 supplemented with Nutridoma containing from 10 to 1000
nM Ang II. In parallel experiments, cells were made quiescent
in DMEM/F12 serum-free medium supplemented with 8 M
insulin for 48 hours. These cells were then incubated with 100
flM Ang II for 2 or 18 hours in serum-free DMEM/F12 with
insulin. Total cellular RNA was extracted from all cells using
acid guanidine thiocyanate-phenol-chloroform as previously
described [30], and either spotted (10 jig) onto nylon filters
(Nytran, Schleicher and Schuell) or resolved by electrophoresis
(10 to 15 tg) using 1% formaldehyde-agarose gels. Following
electrophoresis, the RNA was transferred to nylon filters as
described previously [31]. Filters were pre-incubated in a buffer
composed of 50% formamide, 0.1% SDS, 5x SSPE, 100 j,g/ml
sheared salmon sperm DNA, and 2x Denhardt's solution for
two hours at 37°C. Labeled cDNA probes (10 cpm/filter) were
then incubated with filters for 18 hours at 37°C in a hybridiza-
tion buffer that was identical to the pre-hybridization buffer but
also included 10% dextran sulfate. After hybridization, ifiters
were washed twice in 6x SSPE, 0.1% SDS for 15 minutes at
room temperature followed by two washes in lx SSPE, 0.1%
SDS for 15 minutes at 37°C. The fibronectin probe [32] was a 2.2
kb EcoRI fragment of a human fibronectin eDNA clone
(pFH154). The eDNA probe was labeled with [32P]-dCTP using
a random prime extension kit as described by the manufacturer
(Boehringer Mannheim). The dried filter was exposed to Kodak
XAR-2 film at —70°C with an intensifying screen for three to
five days.
Statistical analysis
Results are expressed as the mean SEM. Significant changes
were determined by one way analysis of variance using the
Newman-Keuls test. To compare changes within groups, re-
sults were analyzed using Student's t-test.
Results
Ang II receptor binding
The specificity of Ang II binding to human fetal mesangial
cells was demonstrated by the ability of Ang II to displace the
binding of [125 I-Sar1,lleu8]Ang II from human fetal mesangial
cells. We identified the presence of Ang II receptor subtypes
using DuP-753, a non-peptide Ang II type 1 receptor (AT1)
antagonist or PD 123177, a non-peptide Ang II type II receptor
(AT2) antagonist. Binding of ['251-Sar1,Ile8]Ang II was com-
pletely inhibited by 10' M AT1 receptor antagonist and not
modified by 106 M AT2 receptor antagonist, suggesting that
cultured human fetal mesangial cells predominantly express
AT1 receptors. To assess whether AT1 receptors were also the
predominant subtype in human fetal kidney, we performed ex
vivo autoradiography using the same antagonists on fetal kidney
sections (Fig. 1). In contrast to cultured human fetal mesangial
cells, 80% of Ang II binding in renal cortex and medulla was
inhibited by the AT2 receptor antagonist PD 123177 (106 M),
while no Ang II binding changes were detectable with the AT1
receptor antagonist DuP-753 (10 M).
Ang II receptor number and affinity of confluent human fetal
mesangial cells grown on plastic, laminin, or fibronectin coated
dishes did not vary significantly (Fig. 2). The Ang II receptor
number on cells grown on plastic, laminin, or fibronectin was 48
3 , 47 4, and 47 3 fmoIIlO5 cells, respectively. Scatchard
analysis of Ang II binding at equilibrium revealed a single class
of binding sites with binding constants of 2.4 n, 3.1 flM and 4.2
n for human fetal mesangial cells grown on plastic, laminin, or
fibronectin, respectively (N = 3, Fig. 1).
Effects of fibronectin and laminin on human fetal mesangial
cells proliferation
To determine the ability of fibronectin to induce mitogenesis,
human fetal mesangial cells were cultured on plastic, lammin,
or fibronectin (20 pg1200 1.d phosphate buffered saline). No
significant difference in human fetal mesangial cell number was
present after four days, whether cells were plated at high
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Fig. 3. Tritiated thymidine incorporation by confluent human fetal
mesangial cells in response to serum or Ang II. DNA synthesis was
estimated by [3H]-thymidine incorporation. After 18 hours incubation
of human fetal mesangial cells with 20% FCS or Ang 11100 flM, 1 lCi/ml
of [3H]-thymidine was added to each well for an additional 4 hours at
37°C. Mesangial cell medium supplemented with 20% fetal calf serum
induced the most significant increase in thymidine incorporation (aver-
age sevenfold, N = 10, P < 0.05). The maximum mitogenic response of
confluent human fetal mesangial cells to Ang II was a twofold increase
over control cells (N = 10, P < 0.05).
density (2 X iO cells/cm2), low density (6 x i0 cells/cm2) or in
the presence or absence of 20% FCS (data not shown). Human
fetal mesangial cell number when plated at high density on
plastic, laminin, or fibronectin in the presence of 20% fetal call
serum was 128,560 3,000; 132,456 2,789; and 124,789
3,216 cells/cm2, respectively. When plated on the same sub-
strates in the absence of FCS serum but with medium supple-
Fig. 2. Scatchard analysis of Ang II binding
to human fetal mesangial cells grown on
plastic, laminin, orfibronectin. Ang II
receptor number and binding affinities were
determined on confluent human fetal
mesangial cells grown on different substrates.
Cells were plated at high density to achieve
confluence in serum-free medium
supplemented with insulin. After 24 hours,
wells with an equal number of cells were used
to quantify Ang II receptor number and
affinity as described in the methods. Ang II
receptor number was 48 3, 47 4, and 47
3 fmol/105 cells when grown on plastic,
laminin, or fibronectin, respectively.
Scatchard analysis of Ang II binding at
equilibrium, generated by the computer
assisted LIGAND program, revealed a single
class of binding sites on human fetal50 mesangial cells grown on different substrates
with binding constants of 2.4 nM, 3.1 nM, and
4.2 nM for plastic, laminin, or fibronectin.
mented with 1% Nutridoma and 8 M insulin as previously
described [12], cell number was 25,876 1,324; 26,785 1,232;
28,678 1,567 cells/cm2, respectively. The final cell number for
human fetal mesangial cells plated at low density in the pres-
ence of serum was not significantly different between groups:
89,456 1,100; 92,456 1,245, 88,987 1,323 cell/cm2 (F>
0.5) for plastic, laminin, and fibronectin, respectively. No
significant differences were found when cells were grown at low
density in the absence of serum: 6,897 245; 7,152 243; 7,034
253 cells/cm2 (P > 0.5), respectively.
Effects of Ang II on human fetal mesangial cell
proIferation
As we have previously reported [3], Ang II increased cell
proliferation of human fetal mesangial cells plated at low and
high density in the absence of serum. Maximum effect, how-
ever, was observed with subconfluent cells. When equal num-
bers of cells were plated in subconfluent wells for four days in
the presence or absence of Ang II, cell number increased to
6,900 250 in control wells and to 10,780 350 cells/cm2 (P <
0.05) with Ang II treatment. This effect was inhibited by the
AT1 receptor antagonist losartan 10 M (7,102 232 cells/cm2)
but not with the AT2 receptor antagonist PD 123177 106 M
(11,283 278 cells/cm2). In a parallel fashion to the expression
of Ang II receptors, Ang Il-induced mitogenic response was not
significantly altered by the following substrates: plastic, lami-
nm, or fibronectin (10,456 298; 11,045 382; 10,780 350
cells/cm2, respectively.)
DNA synthesis
The maximum mitogenic effect of medium on quiescent,
confluent mesangial cells from human fetal kidney (100,000
cells/cm2) was observed with 20% fetal call serum supplemen-
tation. As shown in Figure 3, fetal call serum induced the most
significant increase in thymidine incorporation (20% FCS
16,387 1,678 vs. control 2,345 234; N = 10, P < 0.05). Ang
11(100 nM) also significantly increased thymidine incorporation
in serum-deprived confluent human fetal mesangial cells but to
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Fig. 4. Tritiated thymidine incorporation by
subconfluent human fetal mesangial cells in
response to Ang ii alone and in combination
with Ang II receptor subtype antagonists. The
effect of Ang II receptor antagonists (type I or
type II) on Ang Il-induced thymidine
incorporation was evaluated in subconfiuent
(40,000 cells/cm2) human fetal mesangial cells.
After 18 hours of incubation with Ang II, Ang
II receptor antagonists, or a combination of
both, 1 pCi/ml of [3H]-thymidine was added
to each well for an additional six hours at
37°C. The maximum mitogenic response of
human fetal mesangial cells to Ang II was a
fourfold increase over control cells (N = 15,
P < 0.05) . The AT1 receptor antagonist, DuP
753 (10 M), completely inhibited the
mitogenic response of 100 nM Ang II (N = 15,
P < 0.05). The AT2 receptor antagonist, PD
123177 (10—6 M), did not significantly inhibit
Ang Il-stimulated mitogenic response. Neither
losartan nor PD 123177 independently affected
thymidine incorporation by human fetal
mesangial cells (N = 15).
Angiotensin 11(M)
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secreted II receptor subtypes in the mitogenic effect of Ang II on human
fetal mesangial cells was determined by cotreatment of subcon-
— 10 fluent human fetal mesangial cells with Ang II and Ang II
receptor subtype antagonists. DuP-753 (losartan, an AT1 antag-
onist) at l0— M completely inhibited the mitogenic response of
100 flM Ang II on human fetal mesangial cells (Fig. 4). In
contrast, the AT2 receptor antagonist, PD123 177 at 106 M, did
not affect the mitogenic response to Ang II. Neither losartan
nor PD 123177 alone had a significant effect on thymidine
incorporation by human fetal mesangial cells.
Ang II effect on fibronectin synthesis and steady state mRNA
levels
Fig. 5. Fibronectin synthesis by subconfluent human fetal mesangial
cells in response to Ang II. Immunoprecipitations of secreted and
cell-associated fibronectin from 35S methionine-labeled human fetal
mesangial cells treated with Ang II. Proteins were immunoprecipitated
from samples corrected for equal incorporation of counts. Ang II
treatment significantly increased the production of both secreted and
cell-associated fibronectin by an average of threefold (N = 3).
a lesser extent (Ang II 5,264 213 vs. control 2,345 234; N
= 10, P < 0.05). No significant differences in thymidine
incorporation were detected between Ang TI-treated confluent
cells grown on plastic versus those grown on laminin or
fibronectin.
Consistent with the effect ofAng 11(100 nM) on cell number,
exposure of subconfluent quiescent cells (40,000 cells/cm2) to
Ang II for 18 hours in serum-free medium supplemented with
insulin, resulted in a significant (N = 15, P < 0.05) fourfold
stimulation of thymidine incorporation (Fig. 4). The role of Ang
To explore the role of Ang II on fibronectin synthesis,
immunoprecipitation assays of 35S methionine-labeled proteins
were performed using Ang IT-treated human fetal mesangial
cells (Fig. 5). After the labeling of human fetal mesangial cells
with 35S methionine for two hours in methionine-free medium,
proteins were isolated from medium and cell layers of Ang
TI-treated cells (106 M), immunoprecipitated with anti-
fibronectin antibody, resuspended, and resolved by electro-
phoresis. Ang II induced a 46% increase in TCA-precipitable
radioactivity. When protein lysates containing an equal number
of counts were precipitated with protein G and anti-fibronectin
antiserum, Ang II induced a significant increase in both cell-
associated (control: 1,025 137 and Ang II: 3,843 145 OD
units, P < 0.05) and secreted fibronectin (control 987 98 and
Ang 113,226 123 OD units, P < 0.05). Ang II (10 M and 10_6
M) stimulated fibronectin mRNA in subconfluent human fetal
mesangial cells (Fig. 6 A and C). Within 2 and 18 hours of Ang
II treatment, fibronectin mRNA steady-state expression signif-
icantly increased in subconfluent fetal mesangial cells. The AT1
receptor antagonist losartan alone at 10 M had no effect on
fibronectin mRNA levels. Losartan completely inhibited the
Ang TI-induced increase in fibronectin mRNA (Fig. 6C). In
confluent cells, 20% fetal calf serum or 10_6 M Ang II induced
a similar increased in fibronectin steady-state mRNA expres-
sion after 18 hours of incubation (Fig. 6B).
se
15000
10000-
Angiotensin 11(M) — 10 10-
28 S —
18s—
Ethidium bromide
stained gel
A
Angiotensin 11(M) — — 101 107 1o-
DuP753 (M)
28s—
lBs —
Ethidium bromide
stained gel
10 l0-
28 s—
18s—
Ethidium bromide
stained gel
182 Ray et a!: Ang Ii binding to AT1 receptors
Fig. 6A. Northern analysis of fibronectin steady-state mRNA levels
in subconfluent human fetal mesangial cells in response to increasing
Ang II concentration. After 18 hours of Mg II incubation in the
absence of serum, total cellular RNA was isolated from subconfluent
human fetal mesangial cells and 15 pg of total cellular RNA was
electrophoresed, transferred to nytran, and hybridized with a human
fibronectin probe. The ethidium bromide stained formaldehyde gel
demonstrates equal loading of RNA in each lane. Ang II stimulated a
threefold increase in fibronectin steady state mRNA expression in
subconfluent human fetal mesangial cells. B. Northern analysis of
fibronectin steady-state mRNA levels in confluent human fetal
mesangial cells in response to maximal Mg II stimulation or serum.
Confluent cells were incubated for 18 hours with vehicle or Ang II
(10-6 M) in the absence of serum or with 20% fetal calf serum (FCS).
Fetal calf serum and Ang II induced a similar increase in fibronectin
steady-state mRNA expression in confluent human fetal mesangial
cells. C. Northern analysis of Ang 11-stimulated fibronectin steady-
state mRNA levels of subconfluent human fetal mesangial cells in the
presence of AT1 antagonist. Total cellular RNA was isolated from
subconfluent human fetal mesangial cells following two hours of
incubation with vehicle, Mg II alone, or Ang II in combination with
the AT1 receptor antagonist DuP 753 in the absence of serum. The
AT receptor antagonist had no effect on fibronectin steady-state
mRNA level alone but completely inhibited the Ang Il-induced
increase in fibronectin steady state mRNA level.
Discussion
The importance of Ang II in cardiovascular regulation has
traditionally been viewed in the context of its vasoactive
properties. Increasing evidence, however, suggests a broader
role for Ang II that encompasses cardiovascular and renal
development, vascular responses to injury, and progression of
renal disease [1—6, 33]. Since the glycoprotein fibronectin also
participates in the developmental biology of the cardiovascular
system and is expressed abundantly in vascular and glomerular
diseases, we explored the interrelationship of Ang II and
fibronectin in modulating fetal mesangial cell growth.
In the present study, we have found that only type I Ang II
receptors are present on human fetal mesangial cells in vitro, in
agreement with results from a previous study in human adult
mesangial cells [34]. The Ang II binding data in human fetal
kidney from other investigators [35] and our present data,
however, demonstrate that the majority of Ang II receptors that
are detectable by ex vivo autoradiography in human fetal kidney
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sections are AT2 receptors. There may be many reasons for the
apparent lack of mesangial cells bearing AT2 receptors in vitro,
including: loss of AT2 receptors in culture, in vitro selection for
AT1 receptor-bearing cells, influences of extracellular matrix,
etc. While it is likely that AT1 receptors are present in mesan-
gial cells in human fetal kidney in vivo, they may be below a
level sufficient for detection by autoradiographic methods.
Furthermore, a switch from AT2 to AT1 in culture has been
described in rat skin fibroblasts [361. Thus, the role of AT2
receptors in the modulation of human mesangial proliferation
and metabolism remains to be determined.
Under the experimental serum-free conditions of the current
study, Ang II receptor number and affinity as well as mesangial
cell proliferation were not altered by coating culture dishes with
the extracellular matrix proteins fibronectin or laminin. In the
adult rat, however, soluble fibronectin has previously been
shown to induce a modest proliferation of mesangial cells in
vitro, but these studies were performed in the presence of 0.5%
FBS [17]. The apparent disparity between previous findings and
our current study may be the result of serum cofactors, purity
of fibronectin preparation, or important differences in the
growth kinetics of adult rat and human fetal mesangial cells.
In the present study, Ang II stimulated mitogenesis of human
fetal mesangial cells by binding to AT1 receptors; AT2 receptors
did not appear to participate in this process. Similarly, the
ability of Ang II to stimulate fibronectin expression and protein
synthesis was mediated by AT1 receptors. Thus, the critical
mesangial functions of proliferation and fibronectin synthesis
are mediated by AT1 receptors in vitro, and these effects are
independent of hemodynamic and systemic influence. Whether
these findings are also true in vivo and whether the vasoactive
properties of Ang II can be similarly attributed to a specific
receptor subtype remains to be determined.
Endogenous activation of the renin-angiotensin system is
associated with increased fibronectin synthesis by vascular
smooth muscle cells [8, 18—20]. Exogenously administered Ang
II by infusion also stimulates fibronectin synthesis in rat aorta
[19, 20]. Other conditions that may be associated with systemic
or local angiotensin activation, such as myocyte responses to
cardiac hypertrophy or aortic endotheial cell development, are
also associated with altered fibronectin synthesis [19, 20, 37]. In
the present study, we have found that Ang II directly stimulated
fetal mesangial fibronectin synthesis within two hours in cells
that were rapidly proliferating. This rapid response of fibronec-
tin synthesis to Ang II is consistent with previous suggestions
that fibronectin is a member of a diverse class of rapidly
activated genes that comprise the initial genetic response of
cells to peptide growth factors [38]. In this regard, Ang II may
act in concert with other biologically active proteins to stimu-
late proliferation by human fetal mesangial cells and, thus, may
serve as a competence factor for other growth factors [31.
Of the potential growth factors that may interact with Ang II,
transforming growth factor f3 (TGF-f3) appears to be a likely
candidate. We have previously shown that Ang II stimulation is
associated with increased expression of TGF-/3 in vivo. For
example, dietary potassium depletion and dehydration in young
animals increases circulating levels of Ang II and stimulates the
expression of TGF-32 in juxtaglomerular cells and smooth
muscle cells in renal arterioles [39, 40]. The TGF-/3s are known
to modulate a number of cellular functions including prolifera-
tion, differentiation, and extracellular matrix protein synthesis
[41]. Since Ang II is known to induce TGF-/31 gene expression
in aortic smooth cells [42], TGF-p could play a role in mediating
fibronectin gene expression by Ang II. A potential role for
TGF-p in Ang Il-stimulated proliferation seems less likely since
TGF-f3 inhibits proliferation of subconfluent human fetal me-
sangial cells in vitro.
In summary, we have found that Ang II receptors are present
in large numbers on human fetal mesangial cells in culture and
are of the AT1 subtype. When fetal mesangial cells are exposed
to Ang II, they proliferate and synthesize fibronectin. These
biological effects are mediated by AT1 receptors and are unre-
lated to hemodynamic influence. Whether these same receptors
mediate similar effects in vivo remains to be determined.
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